Aziz Sawaf's most recent trade in Theravance Biopharma Inc was a trade of 9,348 Ordinary Shares done at an average price of $9.5 . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.45 per share. | 20 May 2025 | 9,348 | 364,790 (0%) | 0% | 9.5 | 88,339 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 75,000 | 374,138 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.66 per share. | 20 Feb 2025 | 13,751 | 299,138 (0%) | 0% | 9.7 | 132,835 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.97 per share. | 20 Nov 2024 | 8,477 | 312,889 (0%) | 0% | 10.0 | 84,516 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 20 Aug 2024 | 8,635 | 321,366 (0%) | 0% | 8.2 | 70,980 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.10 per share. | 20 May 2024 | 8,635 | 330,001 (0%) | 0% | 9.1 | 78,579 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 100,000 | 338,636 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 20 Feb 2024 | 17,036 | 238,636 (0%) | 0% | 8.9 | 151,961 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.70 per share. | 20 Aug 2023 | 7,114 | 261,859 (0%) | 0% | 9.7 | 69,006 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 20 May 2023 | 8,744 | 268,973 (0%) | 0% | 11.2 | 98,020 | Ordinary Shares |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 80,000 | 277,717 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.44 per share. | 20 Feb 2023 | 6,783 | 197,717 (0%) | 0% | 10.4 | 70,815 | Ordinary Shares |